Somatrogon
Also known as: hGH-CTP, long-acting growth hormone, MOD-4023, NGENLA, Somatrogon
Source Somatrogon at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Somatrogon (brand name NGENLA®) is a long‑acting recombinant human growth hormone (rhGH) approved in Canada for treating pediatric growth hormone deficiency. Delivered as a once‑weekly subcutaneous injection, it aims to provide growth‑promoting effects comparable to daily rhGH while reducing injection burden.
Mechanism of Action
Somatrogon is engineered to bind and activate the growth hormone receptor, mimicking endogenous GH. Receptor engagement triggers the JAK2‑STAT5 signaling cascade, stimulating hepatic production of insulin‑like growth factor‑1 (IGF‑1) and promoting linear bone growth and protein synthesis. The C‑terminal peptide extension prolongs circulating half‑life, allowing weekly dosing.
What the Research Shows
A phase‑3, 12‑month, open‑label trial in 228 treatment‑naïve children showed somatrogon achieved non‑inferior annualised height velocity (10.10 cm/yr) versus daily somatropin, with similar changes in height SDS and safety profiles. Systematic reviews and meta‑analyses of 16 studies comparing long‑acting GH (including somatrogon) with daily GH found no significant differences in height velocity, safety, or quality‑of‑life outcomes, though many studies had bias concerns. Network meta‑analyses indirectly comparing somatrogon with other weekly GH analogues reported comparable efficacy and safety, but highlighted a higher incidence of injection‑site pain for somatrogon. Cost‑effectiveness data remain lacking.
Reported Benefits
Clinical data demonstrate that somatrogon supports growth rates equivalent to daily GH, offering a once‑weekly regimen that may improve adherence and reduce treatment burden. Safety appears comparable to daily GH, with most adverse events being mild to moderate. Indirect comparisons suggest similar efficacy to other weekly GH analogues.
Limitations of the Evidence
Evidence is limited to short‑term (up to 12 months) pediatric trials and meta‑analyses with moderate risk of bias. Long‑term outcomes, real‑world adherence, and head‑to‑head comparisons with other long‑acting GH products are sparse. Cost‑effectiveness has not been evaluated, and injection‑site discomfort may be more frequent with somatrogon.
Safety Considerations
In the phase‑3 study, about 79 % of participants experienced mild to moderate treatment‑emergent adverse events, similar to daily GH. No new safety signals emerged, but injection‑site pain was reported more often with somatrogon in indirect comparisons. Routine monitoring of IGF‑1 levels and standard GH‑related safety parameters is advised.
How It Is Administered
Somatrogon is administered subcutaneously once weekly. The formulation is supplied as a ready‑to‑inject solution for use in pediatric patients with growth hormone deficiency.
Routes of Administration
Goals & Uses
- Improved Treatment AdherencePatient ConvenienceModerate
- Adult GHD TreatmentEndocrineLow
- Pediatric Growth Hormone Deficiency TreatmentEndocrine / GrowthHigh
- IGF-1 normalizationBiomarker / Surrogate EndpointHigh
- Pediatric growth hormone deficiencyEndocrineHigh
Contraindications
- Prader-Willi syndrome with obesity/respiratory impairmentGenetic / RespiratoryHigh
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- Acute critical illnessCritical CareHigh
- Closed epiphysesSkeletalModerate
- Diabetic retinopathyOphthalmologyModerate
- Hypersensitivity to somatrogon or excipientsImmunologicalModerate
Adverse Effects
- EdemaFluid BalanceUncommonSwelling from fluid retention
- HyperglycemiaMetabolicUncommonAbnormally high blood glucose
- Joint stiffnessMusculoskeletalCommon
- Injection site reactionsLocalCommon
- Injection site painLocalCommonPain at the injection site
- HeadacheNeurologicCommonPain in the head or upper neck
- Intracranial hypertensionNeurologicalRare
- Slipped capital femoral epiphysisMusculoskeletalRare
- Arthralgia / myalgiaMusculoskeletalUncommon
- Elevated IGF-1 levelsEndocrine / LaboratoryCommon
Drug Interactions
- CYP450 substrates (e.g., cyclosporine, anticonvulsants)Low
- InsulinModerateMay increase risk of low blood sugar
- GlucocorticoidsModerate
- Oral hypoglycemic agentsModerate
- Insulin / antidiabetic agentsModerate
- Sex hormones (estrogens)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Hepatic impairmentOrgan FunctionRelative
- Renal impairmentOrgan ImpairmentRelative
- Adults with GH deficiencyAdultRelative
- Neonates / infants < 2 yearsPediatricRelative
- Children with growth hormone deficiencyPediatricAbsolute
- AdultsAdult PopulationRelative
Regulatory Status
- European UnionInvestigationalUnder review as of 2024
- United StatesApprovedApproved: Pediatric growth hormone deficiencyFDA approval 2023 (Ngenla)
- United KingdomInvestigationalPending MHRA approval
Approved by Health Canada in 2021, the EMA in 2022, and the FDA in 2023 for pediatric GHD. Marketed as NGENLA by Pfizer. Not approved for adult GHD or other indications as of current data.
Evidence & Sources
- Journal ArticleModerateLamb YN2022-01-01T00:00:00.000000Z
- Journal ArticleHighMameli C, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateDeal CL, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleHighZhu J, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleHighde Fries Jensen L, et al.2024-01-01T00:00:00.000000Z
Frequently Asked Questions
How does somatrogon differ from daily growth hormone injections?
Somatrogon uses a C‑terminal peptide extension to extend its half‑life, allowing a once‑weekly subcutaneous injection instead of daily dosing. Clinical trials show growth outcomes comparable to daily GH, with a similar safety profile.
Is somatrogon approved for adults with growth hormone deficiency?
Regulatory approval to date is limited to pediatric patients in Canada. While development programs include adults, no approval for adult use has been reported in the cited literature.
What are the common side effects of somatrogon?
Most adverse events are mild to moderate, occurring in roughly 79 % of treated children, and are similar to those seen with daily GH. Injection‑site pain may be more frequent with somatrogon.
Does somatrogon improve treatment adherence?
The weekly dosing schedule reduces injection frequency, which is expected to improve adherence. However, direct adherence data are limited, and real‑world studies are needed to confirm this benefit.
Are there any cost‑effectiveness analyses for somatrogon?
No cost‑effectiveness studies were identified in the reviewed literature. Economic evaluations remain an unmet research need.
What is Somatrogon?
Somatrogon (brand name NGENLA®) is a long‑acting recombinant human growth hormone (rhGH) approved in Canada for treating pediatric growth hormone deficiency. Delivered as a once‑weekly subcutaneous injection, it aims to provide growth‑promoting effects comparable to daily rhGH while reducing injection burden.
What is Somatrogon used for?
Somatrogon is educationally associated with: Improved Treatment Adherence, Adult GHD Treatment, Pediatric Growth Hormone Deficiency Treatment, IGF-1 normalization, Pediatric growth hormone deficiency. Educational only — not medical advice.
How is Somatrogon administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Somatrogon?
Reported adverse effects include: Edema, Hyperglycemia, Joint stiffness, Injection site reactions, Injection site pain, Headache, Intracranial hypertension, Slipped capital femoral epiphysis, Arthralgia / myalgia, Elevated IGF-1 levels. This list is not exhaustive — consult a qualified clinician.
Who should avoid Somatrogon?
Recorded contraindications: Prader-Willi syndrome with obesity/respiratory impairment, Active malignancy, Acute critical illness, Closed epiphyses, Diabetic retinopathy, Hypersensitivity to somatrogon or excipients. Consult a qualified clinician before use.